Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Amlodipine

Amlodipine

Amlodipine: A dihydropyridine calcium channel blocker used to treat hypertension and angina pectoris.
It works by relaxing blood vessels and reduceing the workload on the heart.
PubCompare.ai's AI-powered platform can help optimize your amlodipine research by locating relevant protocols from literature, preprints, and patents, and utilizing data-driven comparisons to identify the best protocols and products for enhanced reproducibility.
Unlock the power of data-driven research optimization with PubCompare.ai.

Most cited protocols related to «Amlodipine»

1
Intensive Blood Pressure Reduction Trial
Cited 97 times
Eligible participants were assigned to a systolic blood-pressure target of either less than 140 mm Hg (the standard-treatment group) or less than 120 mm Hg (the intensive-treatment group). Randomization was stratified according to clinical site. Participants and study personnel were aware of the study-group assignments, but outcome adjudicators were not.
After the participants underwent randomization, their baseline antihypertensive regimens were adjusted on the basis of the study-group assignment. The treatment algorithms were similar to those used in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.22 (link) These algorithms and our formulary are listed in Figures S1 and S2 and Table S1 in the Supplementary Appendix. All major classes of antihypertensive agents were included in the formulary and were provided at no cost to the participants. SPRINT investigators could also prescribe other antihypertensive medications (not provided by the study). The protocol encouraged, but did not mandate, the use of drug classes with the strongest evidence for reduction in cardiovascular outcomes, including thiazide-type diuretics (encouraged as the first-line agent), loop diuretics (for participants with advanced chronic kidney disease), and beta-adrenergic blockers (for those with coronary artery disease).5 (link),27 (link) Chlorthalidone was encouraged as the primary thiazide-type diuretic, and amlodipine as the preferred calcium-channel blocker.28 (link),29 (link) Azilsartan and azilsartan combined with chlorthalidone were donated by Takeda Pharmaceuticals International and Arbor Pharmaceuticals; neither company had any other role in the study.
Participants were seen monthly for the first 3 months and every 3 months thereafter. Medications for participants in the intensive-treatment group were adjusted on a monthly basis to target a systolic blood pressure of less than 120 mm Hg. For participants in the standard-treatment group, medications were adjusted to target a systolic blood pressure of 135 to 139 mm Hg, and the dose was reduced if systolic blood pressure was less than 130 mm Hg on a single visit or less than 135 mm Hg on two consecutive visits. Dose adjustment was based on a mean of three blood-pressure measurements at an office visit while the patient was seated and after 5 minutes of quiet rest; the measurements were made with the use of an automated measurement system (Model 907, Omron Healthcare). Lifestyle modification was encouraged as part of the management strategy. Retention in the study and adherence to treatment were monitored prospectively and routinely throughout the trial.26 (link)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. (2015). The New England journal of medicine, 373(22), 2103-2116.
Publication 2015
Adrenergic beta-Antagonists Amlodipine Antihypertensive Agents azilsartan Calcium Channel Blockers Cardiovascular System Chlorthalidone Chronic Kidney Diseases Coronary Artery Disease Debility Diabetes Mellitus Diuretics Loop Diuretics Office Visits Patients Pharmaceutical Preparations Retention (Psychology) Systolic Pressure Thiazide Diuretics Thiazides Treatment Protocols Vision
2
Evaluating Osteoarthritis Functional Outcomes
Cited 9 times
The Lequesne questionnaire [11 (link)] was modified to incorporate the patient’s weight and height. The Lequesne score is a standardized questionnaire focused on osteoarthritis. It is a 24-scale questionary in which low scores indicate low functional activity (Table 1).

Lequesne score

DrugsTreated patients (mean score)Number of patientsSDpvalue
Adalat® (Nifedipine)4.0530
Amlodipine® (Amlodipine)3.5222.970
Azupamil® (Verapamil)683.590
Carmen® (Lercanidipine)3212.910
Escor® (Nilvadipine)654.720
Felodipine® (Felodipine)574.10
Nifedipine® (Nifedipine)6.2155.210
Nitrendipine® (Nitrendipin)2.182.80
Norvasc® (Amlodipine)4.84850
Verapamil® (Verapamil)6.94950
Control group6.22124.850

SD standard deviation.

It was answered by 400 patients with osteoarthritis (207 women and 193 men). More than 99% of the patients were older than 50 years. Both the control and the active treatment groups have been diagnosed for osteoarthritis for more than 1 year before and the active treatment group has received calcium antagonists for more than 1 year.
Pre-study calculations revealed that 198 patients for each group were required to arrive at a statistical significance of p < 0.05 and a power of 80% for a difference in one unit in the Lequesne score. Matched pairs were established for potential interference variables such as gender, age, and body mass index. The first evaluations of equivalences were performed stepwise with 100, 200, 300, and 400 patients. Finally, a complete equivalence could not be achieved for gender (55% women in the active treatment group and 45% women in the control group) and body mass index (76.27 ± 9.1 kg in the control group).
The Lequesne score correlates significantly with pain and consists of three subscores which were calculated individually and together: pain and discomfort, maximum distance walked, and activities of daily living with a maximum score of 8 for each subscore and a total score of 24 (see Additional file 1). A difference in one score unit is regarded as clinically relevant. The groups were evaluated by the Levene test for equality of variance and by the T-test for equality of the mean.
Daniilidis K., Georges P., Tibesku C.O, & Prehm P. (2015). Positive side effects of Ca antagonists for osteoarthritic joints—results of an in vivo pilot study. Journal of Orthopaedic Surgery and Research, 10, 1.
Full text: Click here
Publication 2015
Amlodipine Calcium Channel Blockers Degenerative Arthritides Felodipine Gender Index, Body Mass lercanidipine Nifedipine nilvadipine Pain Patients Verapamil Woman
3
Extracting Lipid and Diabetes Traits from EMRs
Cited 8 times
EMRs contain structured [International Classification of Diseases or ICD-9 (billing) codes and Current Procedural Terminology or CPT (procedure) codes; clinical lab test results, semi-structured, and unstructured (clinical notes) data, all of which can be used for electronic phenotyping. The data types currently available in the SD that can be accessed for electronic phenotyping include narratives (such as clinical notes, discharge summaries, history and physicals, problem lists, surgical reports, progress notes, letters), ICD-9 codes, CPT codes, forms (intake, assessment), reports [pathology, electrocardiograms (ECGs), echocardiograms], clinical communications, lab values and vital signs, medication orders, TraceMaster (ECGs), and the tumor registry [41 (link)].
Electronic phenotyping has been previously described for BMI in EAGLE BioVU [42 ]. To extract lipid and type 2 diabetes traits from EAGLE BioVU EMRs, laboratory measurements were queried for glucose, HbA1c, HDL-C, insulin, LDL-C, total cholesterol, and triglycerides. Records were also queried for calculated LDL-C. Prescription medication is available in the SD through MedEx [43 (link)], an algorithm that extracts medications and their signature mentions from free-text entries available in the EMR.
For each adult patient (>18 years), median values were calculated for a) measurements taken when no medications are prescribed (“pre-medication” values) and b) measurements taken at first mention of medication and post mention of medication (“post-medication” values). We used the following medication class and list to identify lipid measurements determined at the time or after patients were prescribed lipid-lowering medications

Statins (also known as HMG CoA reductase inhibitors, atorvastatin (Lipitor®), fluvastatin (Lescol®), lovastatin (Mevacor®, Altoprev™), pravastatin (Pravachol®), rosuvastatin calcium (Crestor®), simvastatin (Zocor®), lovastatin + niacin (Advicor®), atorvastatin + amlodipine (Caduet®), and simvastatin + ezetimibe (Vytorin™)

Selective cholesterol absorption inhibitors (ezetimibe (Zetia®))

Resins (cholestyramine (Questran®, Questran® Light, Prevalite®, Locholest®, Locholest® Light), colestipol (Colestid®), colesevelam Hcl (WelChol®))

Fibrates (gemfibrozil (Lopid®), fenofibrate (Antara®, Lofibra®, Tricor®, and Triglide™), clofibrate (Atromid-S))

Niacin

Crawford D.C., Goodloe R., Farber-Eger E., Boston J., Pendergrass S.A., Haines J.L., Ritchie M.D, & Bush W.S. (2015). Leveraging epidemiologic and clinical collections for genomic studies of complex traits. Human heredity, 79(0), 137-146.
Publication 2015
Adult Advicor Amlodipine Anticholesteremic Agents Atorvastatin Atromid Caduet Cholesterol Clofibrate Colesevelam Hydrochloride Colestipol Crestor Diabetes Mellitus, Non-Insulin-Dependent Eagle Echocardiography Electrocardiogram Ezetimibe Fenofibrate Fibrates Fluvastatin Gemfibrozil Glucose Hydroxymethylglutaryl-CoA Reductase Inhibitors Insulin Lescol Light Lipids Lipitor Lofibra Lopid Lovastatin lovastatin-niacin combination Mevacor Neoplasms Niacin Operative Surgical Procedures Patient Discharge Patients Pharmaceutical Preparations Physical Examination Pravachol Pravastatin Questran Resin, Cholestyramine Resins, Plant Rosuvastatin Calcium Signs, Vital Simvastatin Tricor Triglycerides Vytorin Welchol Zetia Zocor
4
Identifying Druggable Genes for SARS-CoV-2 Inhibition
Cited 6 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Amlodipine Cells Clustered Regularly Interspaced Short Palindromic Repeats COVID 19 Drug Interactions Genes Immunofluorescence Infection inhibitors nucleoprotein, Measles virus Pharmaceutical Preparations remdesivir SARS-CoV-2 Screenings, Genetic
5
Longitudinal Study of Gut Microbiome Changes During Antibiotic Therapy
Cited 6 times
Fresh faecal samples were collected from a patient who had not taken ABs within the previous 3 months. The patient (a 68-year-old man) was admitted to the Department for Internal Medicine at the University Hospital Kiel (Germany) due to an infected cardiac pacemaker. A clinical examination identified inflamed skin and subcutaneous tissue around the pacemaker, and laboratory findings revealed an elevated C-reactive protein level (CRP 19.7 mg/litre; normal value <8 mg/litre) and a full blood count within normal ranges. The patient did not present any intestinal disorders. The pacemaker had been placed to treat the patient's sick sinus syndrome, first diagnosed in 1994. His cardiovascular risk factors were arterial hypertension and non-insulin-dependent diabetes mellitus. The patient was regularly taking amlodipine, ramipril, hydrochlorothiazide and glimepiride on a daily basis and Marcumar according to his international normalised ratio values. AB therapy was initiated with a combined intravenous therapy of ampicillin/sulbactam and cefazolin on the day of admission as a single dose and continued with intravenous cefazolin alone for the next 14 days. The patient's CRP level returned to normal within 1 week after the beginning of AB therapy. Faecal samples were collected on the day of admission, prior to AB treatment (day 0, FS-0), on days 3, 6, 11 and 14 of AB treatment (FS-3, FS-6, FS-11 and FS-14, respectively) and 40 days after AB therapy (FS-40). Fresh faeces were collected, frozen immediately and stored at −80°C until further processing. Informed consent was obtained from the patient, and the study was approved by the Ethical Board of the Medical Faculty of the Christian-Albrecht-University, Kiel, Germany. The patient provided written informed consent. Full descriptions of the materials and methods used for the following are available in the Materials and Methods in the online supplement: nucleic acid and RNA extraction; 16S rDNA and 16S rRNA sequencing; metagenome sequencing; mRNA purification, amplification and sequencing; metagenomic and metatranscriptomic analysis; protein extraction, separation and identification and data processing; and metabolite extraction, separation and identification and data processing. All sequences have been entered in the European Bioinformatics Institute database, under accession number ERP001506.
Pérez-Cobas A.E., Gosalbes M.J., Friedrichs A., Knecht H., Artacho A., Eismann K., Otto W., Rojo D., Bargiela R., von Bergen M., Neulinger S.C., Däumer C., Heinsen F.A., Latorre A., Barbas C., Seifert J., dos Santos V.M., Ott S.J., Ferrer M, & Moya A. (2012). Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut, 62(11), 1591-1601.
Publication 2012
Amlodipine ampicillin-sulbactam Cefazolin Complete Blood Count C Reactive Protein Diabetes Mellitus, Non-Insulin-Dependent Dietary Supplements Europeans Faculty, Medical Feces Freezing glimepiride High Blood Pressures Hydrochlorothiazide International Normalized Ratio Intestinal Diseases Marcoumar Metagenome Nucleic Acids Pacemaker, Artificial Cardiac Patients Physical Examination Proteins Psychotherapy, Multiple Ramipril Recombinant DNA RNA, Messenger RNA, Ribosomal, 16S Sick Sinus Syndrome Skin Subcutaneous Fat Therapeutics

Most recents protocols related to «Amlodipine»

1
Protein C and S Deficiency in Pregnancy Losses
This study was conducted at Santosh Medical College, Department of Physiology, in collaboration with the Department of Obstetrics and Gynaecology, Guru Multi Speciality Hospital, Kashmir. Ethical clearance was obtained from the institutions before carrying out the study.
This prospective cross-sectional study was conducted over one year, from Dec 2020 to Dec 2021. Given the low prevalence of protein C and S deficiency worldwide, which is estimated to be around 3 cases per thousand individuals, the presumed prevalence value of 0.003 was used in the PASS software while applying the Exact Clopper Pearson method. The estimated sample size for the prospective study group was determined to be n=38. This sample size provides a two-sided 95% confidence interval with a width of 0.098.
Using a mathematical relationship between the F distribution and the cumulative binomial distribution, the lower and upper confidence limits of a 100 (1-a)% exact confidence interval for the true proportion p are given by:
In the present study, 80 pregnant women were recruited and divided into two groups for analysis. Group A, also known as the case group, consisted of 40 women who experienced three or more miscarriages in the first or second trimester of pregnancy. Group B, also known as the control group, consisted of 40 healthy pregnant women in their third trimester.
We collected a detailed history from each participant, including demographic profile and comprehensive obstetric and drug history. Additionally, we collected data on their current symptoms, including leg pain, chest discomfort with breathlessness, weakness on one side of the body, and history of deep vein thrombosis (DVT), stroke, low birth weight (LBW), and intrauterine growth retardation (IUGR). Following this, a detailed general and local examination was performed by the concerned gynecologist. This examination included checking vital signs, body mass index (BMI) and performing an abdominal and pelvic examination. Finally, a series of routine laboratory tests were recommended (complete blood count, urine analysis, blood glucose, thyroid profile, Protein C and S), and an ultrasound was performed. Hypertensive patients received multivitamins, progesterone support, and amlodipine.
In addition to the laboratory tests, we also analyzed the antenatal ultrasound for each case. Most of the cases showed normal results on ultrasound, except for a few cases with low levels of protein C and S, which showed signs of IUGR on ultrasound. To further investigate these cases, we performed a Doppler flow study to evaluate any signs of reduced umbilical blood flow, which could indicate the presence of thrombosis. Patients were followed up with laboratory results, and those with low protein C and S levels were prescribed low molecular weight heparin (LMWH) by the gynecologist as an additional treatment to prevent thrombotic events.
Mukhtar B., Garg R., Ibrahim G, & Batra J. (2023). Investigating protein C and S levels in pregnant women with recurrent early pregnancy loss versus normal pregnancy. Journal of Medicine and Life, 16(1), 160-166.
Full text: Click here
Publication 2023
Abdomen Amlodipine Blood Circulation Blood Glucose Cerebrovascular Accident Chest Complete Blood Count Deep Vein Thrombosis Diet, Protein-Restricted Dyspnea Fetal Growth Retardation Gynecologist Hemiparesis Heparin, Low-Molecular-Weight Index, Body Mass Miscarriage Pain Patients Pelvic Examination Pharmaceutical Preparations physiology Pregnant Women Progesterone Protein C Signs, Vital Thrombosis Thyroid Gland Ultrasonography Umbilicus Urinalysis Woman
2
Hypertensive Rat Model Interventions
In this study, 12 male normotensive Wistar Kyoto rats (WKY/NCrl) and 36 male spontaneously hypertensive rats (SHR/NCrl) were used. Hypertensive rats were randomly allocated to three different experimental groups: 12 untreated rats (SHR Ctrl), 12 rats treated with amlodipine (SHR Amlo), and 12 rats treated with atenolol (SHR Aten). WKY rats were left untreated and served as a normotensive control group (WKY Ctrl). One untreated SHR and one atenolol-treated SHR died during the study from unknown causes, leaving 11 rats in both of these groups. All animals were obtained from Charles River (Germany) and were 4 weeks of age upon arrival in the animal facility. They were housed in groups of 2 rats per cage on a 12-h light/12-h dark schedule and had ad libitum access to standard laboratory food and drinking water. All experiments were performed in a blinded fashion and were in accordance with the ARRIVE guidelines and European Union guidelines for the welfare of laboratory animals (Directive 2010/63/EU), and were approved by the Academic Medical Center Animal Ethics Committee. All in vivo experiments were carried out under isoflurane inhalation anaesthesia (Pharmachemie B.V.).
Naessens D.M., de Vos J., Richard E., Wilhelmus M.M., Jongenelen C.A., Scholl E.R., van der Wel N.N., Heijst J.A., Teunissen C.E., Strijkers G.J., Coolen B.F., VanBavel E, & Bakker E.N. (2023). Effect of long-term antihypertensive treatment on cerebrovascular structure and function in hypertensive rats. Scientific Reports, 13, 3481.
Full text: Click here
Publication 2023
Amlodipine Anesthesia, Inhalation Animal Ethics Committees Animals Animals, Laboratory Atenolol Food Isoflurane Light Males Rats, Inbred SHR Rats, Inbred WKY Rattus norvegicus Rivers
3
Evaluating Amlodipine Dosage in Patients
Quantitative variables were described with arithmetical mean and standard deviation (SD) or median and the first (Q1) and third (Q3) quartiles, if data were not normally distributed. The independent samples t-test was used to test the difference in age between gender, as data were normally distributed and homogenous as assessed using the Shapiro-Wilk test with normal Q-Q plots and Levene’s test, respectively. The difference of dose of amlodipine between age groups was tested using the Mann-Whitney U test, because data were not normally distributed. Categorical or qualitative variables were characterized as number and percentage. Categorical variables were compared with Pearson χ2 test or Fisher exact test, depending on the violation or satisfaction of the assumption. The statistical analyzes were performed using SPSS 26 (IBM, Chicago, IL, USA) and G*Power 3.1.9. software (Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany). Differences were considered statistically significant at p < 0.05.
Kustovs D., Urtāne I., Sevostjanovs E., Moreino E, & Trušinskis K. (2023). Opportunities of Amlodipine as a Potential Candidate in the Evaluation of Drug Compliance during Antihypertensive Therapy. Medicina, 59(2), 340.
Full text: Click here
Publication 2023
Age Groups Amlodipine Gender Homozygote Satisfaction
4
Rare HIV-1 Controller with Antiretroviral Resistance
The 59- year-old controller (subject #1) was diagnosed with HIV-1 infection when he was treated in the hospital for recurrent epileptic seizures. Since an ischemic stroke seven years previously he had suffered from hemiparesis of his right leg and right arm. He was a smoker with hypertonic blood pressure. The time point of HIV-1 infection is not known but was established to have occurred prior to his severe neurological disability.
At diagnosis, he displayed a CD4 count of 1004 cells/µL and HIV-1-specific antibodies measured by ELISA (ARCHITECT HIV Ag/Ab Combo Assay, Abbott, Wiesbaden, Germany) and immunoblot (Geenius HIV 1/2 Confirmatory Assay, Bio-Rad laboratories, Feldkirchen, Germany). He maintained normal CD4 counts >800 cells/µL over the next 453 days post-diagnosis (Table 1). His viral load measured by real-time HIV-1 PCR (Abbott RealTime HIV-1 assay, Abbott, Wiesbaden) was 40 copies/mL at diagnosis. with subsequent low viral loads ranging between <20 and 20 copies/mL until day 293 post-diagnosis (Table 1). At day 383, four weeks after a traumatic subarachnoid hemorrhage and fracture of his right humerus, he displayed a transient increase of viral load to 250 copies/mL with spontaneous decline to <20 copies/mL at day 453. A resistance analysis from plasma obtained at day 383 post-diagnosis revealed the presence of several mutations in reverse transcriptase (RT, 41L, 210W, 215A) and protease (33F, 43T, 46L, 53L, 82A, 88D) which were associated with high-level resistance against zidovudine, stavudine and several protease inhibitors. This indicated the transmission of a drug-resistant virus as the patient has not been treated with antiretroviral drugs in the past.
At the time point of his first viral load measurement, he was treated with the following drugs: lamotrigine, levetiracetam, lacosamide, simvastatin, acetylsalicylic acid, ramipril, amlodipine, melperone, baclofen, citalopram and thiamine. The patient’s HLA-type was HLA A*11, B*52, B*57, C*6, C*12.
In addition to the controller (subject #1), we investigated 14 HLA-B*52-positive, HIV-1-infected patients (clinical characteristics shown in Table S1). All were on antiretroviral combination therapy (cART) for a median time of 75 months (range 3–315 months). They presented with a current median viral load of <20 copies/mL (range: <20 to 40 copies/mL) and a current median CD4 count of 872 (range 351–1434).
El Kenz B., Schmidt K.G., Ogungbemi-Alt V.K., Bergmann S., Steininger P., Korn K., Spriewald B., Harrer E.G., Nganou-Makamdop K, & Harrer T. (2023). Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller. Viruses, 15(2), 567.
Full text: Click here
Publication 2023
Amlodipine Aspirin Baclofen Biological Assay Blood Pressure CD4+ Cell Counts Cells Citalopram Combination Antiretroviral Therapy Diagnosis Disabled Persons Enzyme-Linked Immunosorbent Assay Epilepsy Hemiparesis HIV-1 HIV-2 HIV Antibodies HIV Infections HLA-B Antigens HLA Typing Humeral Fractures Immunoblotting Infection Lacosamide Lamotrigine Levetiracetam metylperon Mutation Patients Peptide Hydrolases Pharmaceutical Preparations Plasma Protease Inhibitors Ramipril Real-Time Polymerase Chain Reaction RNA-Directed DNA Polymerase Simvastatin Stavudine Stroke, Ischemic Subarachnoid Hemorrhage, Traumatic Thiamine Transients Transmission, Communicable Disease Virus Zidovudine
5
Bioequivalence of Amlodipine Combination Formulations
Cited 1 time
Data were obtained from eight bioequivalence trials that compared a test and a reference formulation of amlodipine combined with other antihypertensive or hypocholesterolemic agents. A single oral dose was administered under fasting conditions in all trials, which were phase I, open-label, single-center, crossover and randomized with two sequences and two periods for amlodipine. In clinical trial A, amlodipine/atorvastatin (10/10 mg) film-coated tablets were compared with Caduet® film-coated tablets (Pfizer S.A.) at the same dose. Amlodipine/valsartan (10 mg/160 mg) film-coated tablets were compared with Exforge® film-coated tablets (Novartis) at the same dose in clinical trial B. In clinical trials C, D and E, amlodipine/valsartan/hydrochlorothiazide (HTZ) (10/320/25 mg) film-coated tablets were compared with Exforge HCT® film-coated tablets (Novartis Europharm Limited) at the same dose. In clinical trials F, G and H, the test formulations were olmesartan/amlodipine/HTZ (40/10/12.5 mg) film-coated tablets, which were compared with Sevikar HCT® (Daiichi Sankyo Spain, S.A) or with Olmetec Plus® (Daiichi Sankyo Spain, S.A) and Norvas® (Pfizer S.A.) tablets, both 40/10/12.5 mg. The wash-out time between the two periods was 14 days for clinical trials A to E and 21 days for clinical trials F to H. In both periods in all clinical trials, volunteers were confined at UECHUP since 10 p.m. of the day before drug administration (day 0). Drug administration took place at 9:00 a.m. (day 1), and blood samples were extracted at different times for amlodipine plasmatic quantification and for genotyping. Volunteers from clinical trials C to H stayed at UECHUP until 9:30 p.m. (day 1) and volunteers from clinical trials A and B stayed until 9:30 a.m. (day 2). All the volunteers visited UECHUP for additional blood extractions at 24, 48 and 72 h after drug administration. The studies were blinded only for the plasma concentration determination of both formulations. In all of them, the test formulation was demonstrated to be bioequivalent to the reference for amlodipine. Therefore, the arithmetic mean of the pharmacokinetic parameters of both formulations was calculated for each volunteer.
Soria-Chacartegui P., Zubiaur P., Ochoa D., Villapalos-García G., Román M., Matas M., Figueiredo-Tor L., Mejía-Abril G., Calleja S., de Miguel A., Navares-Gómez M., Martín-Vilchez S, & Abad-Santos F. (2023). Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety. Pharmaceutics, 15(2), 404.
Full text: Click here
Publication 2023
Amlodipine amlodipine - atorvastatin Amlodipine-Valsartan Antihypertensive Agents BLOOD Caduet Exforge Exforge HCT Hydrochlorothiazide olmesartan Olmetec Plasma Voluntary Workers

Top products related to «Amlodipine»

1
Amlodipine by Merck Group
Sourced in United States
Amlodipine is a lab equipment product manufactured by Merck Group. It is a calcium channel blocker that inhibits the movement of calcium ions into the muscle cells of the heart and blood vessels. This mechanism of action can help regulate blood pressure and improve cardiovascular function.
2
Phoenix winnonlin by Pharsight
Sourced in United States
Phoenix WinNonlin is a comprehensive software suite designed for pharmacokinetic and pharmacodynamic (PK/PD) analysis. It provides robust tools for data modeling, simulation, and reporting across various drug development stages.
3
Formic acid by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.
4
Mastersizer s by Malvern Panalytical
Sourced in United Kingdom
The Mastersizer S is a laser diffraction particle size analyzer developed by Malvern Panalytical. It is designed to measure the size distribution of particles suspended in a liquid or gas medium.
5
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
6
Phenylephrine by Merck Group
Sourced in United States, United Kingdom, Germany, Japan, Sao Tome and Principe, Australia, Brazil, Switzerland, Italy, France, Czechia
Phenylephrine is a pharmaceutical product used as a laboratory reagent. It functions as a sympathomimetic amine, which means it stimulates the sympathetic nervous system. Phenylephrine is commonly used in various research and analytical applications.
7
L name by Merck Group
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, France, Brazil, Italy, Belgium, China, Canada, Spain
L-NAME is a synthetic compound that functions as a nitric oxide synthase inhibitor. It is commonly used in research applications to study the role of nitric oxide in biological processes.
8
Filtermax f5 multi mode microplate reader by Molecular Devices
Sourced in United States, Japan
The FilterMax F5 Multi-Mode Microplate Reader is a compact and versatile lab equipment designed for absorbance and fluorescence measurements. It features a high-performance optical system and supports 6- to 384-well microplates. The instrument can perform a range of detection modes, including endpoint, kinetic, and spectral scanning.
9
Norvasc by Pfizer
Sourced in United States, Japan
Norvasc is a prescription medication used to treat high blood pressure and angina (chest pain). It is a calcium channel blocker that works by relaxing and widening blood vessels, which helps to lower blood pressure and improve blood flow to the heart.
10
Acetonitrile by Avantor
Sourced in United States, Germany, France, Poland, Italy, United Kingdom, Spain, Belgium, Hungary, Netherlands, Canada, Switzerland, Sweden, Brazil, India, Denmark, Austria, Norway, China, Mexico, Japan, Finland, Ireland, Australia
Acetonitrile is a colorless, volatile, and flammable organic solvent used in various laboratory applications. It is a polar aprotic solvent with a high dielectric constant, making it a suitable choice for a wide range of chemical reactions and extractions.

More about "Amlodipine"

Amlodipine is a dihydropyridine calcium channel blocker commonly used to treat hypertension and angina pectoris.
It works by relaxing blood vessels and reducing the workload on the heart.
This medication is known by the brand name Norvasc.
Amlodipine can be analyzed using various analytical techniques such as Phoenix WinNonlin software for pharmacokinetic data analysis, Mastersizer S for particle size measurement, and a FilterMax F5 Multi-Mode Microplate Reader for optical density measurements.
In research settings, Amlodipine may be formulated with excipients like Formic acid and Acetonitrile.
Additionally, Amlodipine's mechanisms of action can be studied by utilizing vasodilatory agents like Phenylephrine and L-NAME.
PubCompare.ai's AI-powered platform can help optimize your amlodipine research by locating relevant protocols from literature, preprints, and patents, and utilizing data-driven comparisons to identify the best protocols and products for enhanced reproducibility.
Unlocking the power of data-driven research optimization with PubCompare.ai can lead to more efficient and reproducible Amlodipine-related studies.